Crinetics Pharmaceuticals Inc. (CRNX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Crinetics Pharmaceuticals...

    NASDAQ: CRNX · Real-Time Price · USD
    40.77
    -0.74 (-1.78%)
    At close: Oct 03, 2025, 1:23 PM

    Crinetics Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 1.04M 4.01M 4.74M 1.08M
    Cost of Revenue
    		 n/a 1.1M 1.39M 1.26M
    Gross Profit
    		 1.04M 4.01M 3.35M -184K
    Operating Income
    		 -338.85M -222.61M -167.88M -107.7M
    Interest Income
    		 41.44M 13.44M 4.32M 157K
    Pretax Income
    		 -298.41M -214.53M -163.92M -107.64M
    Net Income
    		 -298.41M -214.53M -163.92M -107.64M
    Selling & General & Admin
    		 99.74M 58.09M 42.39M 24.52M
    Research & Development
    		 240.16M 168.53M 130.22M 84.25M
    Other Expenses
    		 -2.79M n/a -1.39M -1.26M
    Operating Expenses
    		 337.11M 226.62M 171.23M 107.52M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 339.89M 226.62M 172.62M 108.78M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 80.78M 58.07M 51.98M 38.44M
    Shares Outstanding (Diluted)
    		 80.78M 58.07M 51.98M 38.44M
    EPS (Basic)
    		 -3.69 -3.69 -3.15 -2.8
    EPS (Diluted)
    		 -3.69 -3.69 -3.15 -2.8
    EBITDA
    		 -338.85M -221.51M -166.9M -106.78M
    EBIT
    		 -338.85M -222.61M -167.88M -107.7M
    Depreciation & Amortization
    		 2.79M 1.1M 1.39M 1.26M

    Add to Watchlist